Patents by Inventor Paul Maddon
Paul Maddon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080015348Abstract: Disclosed herein are isolated nucleic acids encoding a first polypeptide comprising a heavy chain of an anti-CCR5 antibody or a portion thereof containing three CDR regions, wherein the three CDR regions comprise consecutive amino acids, the sequences of such consecutive amino acids being identical to the sequences of CDR regions present in a heavy chain of a monoclonal antibody selected from the group: PA14, PA8, PA9, PA10, PA11, and PA12; and wherein the first polypeptide in combination with a second polypeptide comprising a light chain of an anti-CCR5 antibody binds to an epitope of CCR5 comprising amino acid residues in (1) an N-terminus of CCR5, (2) one of three extracellular loop regions of CCR5, or (3) a combination of (1) and (2).Type: ApplicationFiled: May 24, 2007Publication date: January 17, 2008Inventors: William Olson, Paul Maddon
-
Publication number: 20070274986Abstract: This invention provides a composition which comprises a monoclonal antibody or a fragment of such antibody, wherein the monoclonal antibody or fragment of such antibody binds to the same epitope as antibody PA14 produced by a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) and a carrier. This invention also provides a method of treating a subject infected with HIV-1 which comprises administering to the subject an effective dose of the composition of the invention.Type: ApplicationFiled: May 17, 2007Publication date: November 29, 2007Inventors: William Olson, Paul Maddon
-
Publication number: 20070231327Abstract: This invention provides a monoclonal antibody or a fragment of such antibody, wherein the antibody or the fragment of such antibody binds to the same epitope as monoclonal antibody PA14 produced by the hybridoma cell line designated PA14 (ATCC Accession No. HB12610). This invention also provides a hybridoma cell line designated PA14 (ATCC Accession No. HB-12610) which produces a monoclonal antibody designated PA14.Type: ApplicationFiled: May 23, 2007Publication date: October 4, 2007Inventors: William Olson, Paul Maddon
-
Publication number: 20070160617Abstract: This invention relates generally to antibody-drug conjugates (ADCs). In particular, the invention relates to ADCs which comprise an antibody or antigen-binding fragment thereof which binds to prostate-specific membrane antigen (PSMA) and is conjugated to monomethylauristatin norephedrine or monomethylauristatin phenylalanine. The antibody-drug conjugate has a PC-3™ cell to C4-2 or LNCaP™ cell selectivity of at least 250. The invention also relates, in part, to compositions of and methods of using the ADCs. The methods provided include, for example, methods for treating a PSMA-mediated disease.Type: ApplicationFiled: June 20, 2006Publication date: July 12, 2007Applicant: PSMA Development Company, LLCInventors: Dangshe Ma, Paul Maddon, William Olson, Svetlana Doronina, Brian Toki, Peter Senter
-
Publication number: 20070048820Abstract: This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies.Type: ApplicationFiled: October 25, 2005Publication date: March 1, 2007Inventors: Graham Allaway, Virginia Litwin, Paul Maddon
-
Publication number: 20070031408Abstract: The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.Type: ApplicationFiled: October 16, 2006Publication date: February 8, 2007Inventors: William Olson, Paul Maddon, Naoya Tsurushita, Paul Hinton, Maximillano Vasquez
-
Publication number: 20070026441Abstract: This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.Type: ApplicationFiled: July 21, 2006Publication date: February 1, 2007Inventors: William Olson, Paul Maddon, Daniel Pevear, Robert Israel, Jose Murga
-
Publication number: 20070025983Abstract: This invention provides an antibody capable of specifically inhibiting the fusion of an HIV-1 envelope glycoprotein+ cell with an appropriate CD4+ cell without cross reacting with the HIV-1 envelope glycoprotein or CD4 and capable of inhibiting infection by one or more strains of HIV-1. This antibody is then used to identify a molecule which is important for HIV infection. Different uses of the antibody and the molecule are described.Type: ApplicationFiled: October 5, 2006Publication date: February 1, 2007Inventors: Virginia Litwin, Graham Allaway, Paul Maddon
-
Publication number: 20070020280Abstract: This invention provides a composition which comprises an admixture of three compounds, wherein: (a) one compound is an antibody which binds to a CCR5 receptor; (b) one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell; and (c) one compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate; wherein the relative mass ratio of any two of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell. This invention also provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the composition of the subject invention effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.Type: ApplicationFiled: September 12, 2006Publication date: January 25, 2007Inventors: William Olson, Paul Maddon
-
Publication number: 20060233798Abstract: This invention provides a method of reducing an HIV infected subject's HIV-1 viral load which comprises administering to the subject an effective viral load reducing amount of an antibody which (a) binds to a CCR5 chemokine receptor and (b) inhibits fusion of HIV-1 to a CD4+CCR5+ cell, so as to thereby reduce the subject's HIV-1 viral load to 50% or less of the subject's HIV-1 viral load prior to administering the antibody to the subject.Type: ApplicationFiled: June 12, 2006Publication date: October 19, 2006Inventors: William Olson, Paul Maddon
-
Publication number: 20060198855Abstract: This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGNR protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. Compounds of the present invention inhibit HCV infection of cells susceptible to HCV infection.Type: ApplicationFiled: April 4, 2006Publication date: September 7, 2006Inventors: William Olson, Paul Maddon
-
Publication number: 20060194244Abstract: This invention provides a polypeptide comprising a fragment of a chemokine receptor capable of inhibiting HIV-1 infection. In an embodiment, the chemokine receptor is C-C CKR-5. In another embodiment, the fragment comprises at least one extracellular domain of the chemokine receptor C-C CKR-5. This invention further provides different uses of the chemokine receptor for inhibiting HIV-1 infection.Type: ApplicationFiled: April 7, 2006Publication date: August 31, 2006Inventors: Graham Allaway, Tatjana Dragic, Virginia Litwin, Paul Maddon, John Moore, Alexandra Trkola
-
Publication number: 20060140977Abstract: This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies.Type: ApplicationFiled: October 25, 2005Publication date: June 29, 2006Inventors: Graham Allaway, Virginia Litwin, Paul Maddon
-
Publication number: 20060094049Abstract: This invention provides an isolated nucleic acid which comprises a nucleotide segment having a sequence encoding a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention also provides a viral envelope protein comprising a viral surface protein and a corresponding viral transmembrane protein wherein the viral envelope protein contains one or more mutations in amino acid sequence that enhance the stability of the complex formed between the viral surface protein and transmembrane protein. This invention further provides methods of treating HIV-1 infection.Type: ApplicationFiled: October 28, 2005Publication date: May 4, 2006Inventors: James Binley, Norbert Schuelke, William Olson, Paul Maddon, John Moore
-
Publication number: 20060051373Abstract: This invention provides a first composition comprising a pharmaceutically acceptable particle and a stable HIV-1 pre-fusion envelope glycoprotein trimeric complex operably affixed thereto. This invention further provides a second composition comprising (a) a pharmaceutically acceptable particle, (b) an antigen, and (c) an agent which is operably affixed to the particle and is specifically bound to the antigen, whereby the antigen is operably bound to the particle. Finally, this invention provides related nucleic acids, vectors, cells, compositions, production methods, and prophylactic and therapeutic methods.Type: ApplicationFiled: September 6, 2002Publication date: March 9, 2006Inventors: William Olson, Norbert Schulke, Jason Gardner, Paul Maddon
-
Publication number: 20060029932Abstract: This invention provides methods for inhibiting fusion of HIV-1 to CD4? cells which comprise contacting CD4? cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited. This invention also provides methods for inhibiting HIV-1 infection of CD4+ cells which comprise contacting CD4+ cells with a non-chemokine agent capable of binding to a chemokine receptor in an amount and under conditions such that fusion of HIV-1 to the CD4+ cells is inhibited, thereby inhibiting the HIV-1 infection. This invention provides non-chemokine agents capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells. This invention also provides pharmaceutical compositions comprising an amount of the non-chemokine agent capable of binding to the chemokine receptor and inhibiting fusion of HIV-1 to CD4+ cells effective to prevent fusion of HIV-1 to CD4+ cells and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 5, 2005Publication date: February 9, 2006Inventors: Graham Allaway, Virginia Litwin, Paul Maddon, William Olson
-
Publication number: 20050215472Abstract: The invention includes stable multimeric, particularly dimeric, forms of PSMA protein, compositions and kits containing dimeric PSMA protein as well as methods of producing, purifying and using these compositions. Such methods include methods for eliciting or enhancing an immune response to cells expressing PSMA, including methods of producing antibodies to dimeric PSMA, as well as methods of treating cancer, such as prostate cancer.Type: ApplicationFiled: October 27, 2004Publication date: September 29, 2005Applicant: PSMA Development Company, LLCInventors: Norbert Schulke, Paul Maddon, William Olson
-
Publication number: 20050089526Abstract: This invention provides stable HIV-1 pre-fusion envelope glycoprotein trimeric complexes. This invention also provides related polypeptides and compositions comprising pharmaceutically acceptable particles and the trimeric complexes operably affixed thereto. This invention further provides related nucleic acids, vectors, host cells, compositions, production methods, and prophylactic and therapeutic methods.Type: ApplicationFiled: September 6, 2002Publication date: April 28, 2005Inventors: John Moore, James Binley, Min Lu, William Olson, Norbert Schulke, Jason Gardner, Paul Maddon, Rogier Sanders